MGC Pharmaceuticals Limited Non-Deal Roadshow Presentation December 2023

TIDMMXC

MGC Pharmaceuticals Limited

18 December 2023

MGC Pharmaceuticals Ltd.

Non-Deal Roadshow Presentation December 2023

18 December 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd (MGC Pharma, MGC or the Company), a European based pharmaceutical company specialising in the production and development of innovative medicines for unmet medical needs, announces the publication of its non-deal roadshow presentation for December 2023 which may be accessed via the following link http://www.rns-pdf.londonstockexchange.com/rns/1411X_1-2023-12-18.pdf .

- Ends-

Authorised for release by the board of directors, for further information please contact:

 
 MGC Pharmaceuticals Ltd            MGC Pharmaceuticals Ltd 
  Roby Zomer                         Rowan Harland 
  CEO & Managing Director            Company Secretary 
  [phone]                    [phone] 
  [e-mail]               [e-mail] 
 UK IR/PR Advisers                  UK Brokers 
  IFC Advisory                       Oberon Capital 
  Graham Herring / Tim Metcalfe /    Aimee McCusker / Adam Pollock 
  Zach Cohen                         [phone] 
  [phone]                   [e-mail] 
  [e-mail]     [e-mail] 
 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European pharmaceutical company with a strong commitment to creating accessible and ethically produced cutting-edge medicines. Our approach combines in-house research with innovative technologies, all aimed at discovering and producing treatments for currently unmet medical conditions.

The company's founders and executives are distinguished figures in the global pharmaceutical industry. Our central business strategy revolves around the development and supply of innovative medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia.

MGC Pharma maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products currently in the developmental stages. We've established strategic partnerships with renowned institutions and academia, fostering the optimization of our medicines' development. These medicines are produced in our EU-GMP Certified manufacturing facilities, ensuring the highest quality standards.

With a growing patient base in key regions like the USA, UK, Australia, and Ireland, MGC Pharma has also built a global distribution network through a wide-reaching group of commercial partners. This extensive network places us in a prime position to supply the global market effectively.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFFDSUAEDSESE

(END) Dow Jones Newswires

December 18, 2023 04:06 ET (09:06 GMT)